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Abstract
The infiltrative behavior of diffuse gliomas severely reduces therapeutic potential of surgical resection and radiotherapy,
and urges for the identification of new drug-targets affecting glioma growth and migration. To address the potential
role of protein tyrosine phosphatases (PTPs), we performed mRNA expression profiling for 91 of the 109 known human
PTP genes on a series of clinical diffuse glioma samples of different grades and compared our findings with in silico
knowledge from REMBRANDT and TCGA databases. Overall PTP family expression levels appeared independent of
characteristic genetic aberrations associated with lower grade or high grade gliomas. Notably, seven PTP genes
(DUSP26, MTMR4, PTEN, PTPRM, PTPRN2, PTPRT and PTPRZ1) were differentially expressed between grade II-III gliomas
and (grade IV) glioblastomas. For DUSP26, PTEN, PTPRM and PTPRT, lower expression levels correlated with poor
prognosis, and overexpression of DUSP26 or PTPRT in E98 glioblastoma cells reduced tumorigenicity. Our study
represents the first in-depth analysis of PTP family expression in diffuse glioma subtypes and warrants further
investigations into PTP-dependent signaling events as new entry points for improved therapy.
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Introduction
Gliomas arise from glial (precursor) cells and represent
the most frequent type of primary brain tumor. The vast
majority is classified as diffuse gliomas, reflecting their
infiltrative growth into the brain parenchyma along mye-
linated axon bundles and blood vessels [1, 2]. Diffuse
gliomas are histopathologically graded into WHO grades
II-IV, with grade IV astrocytoma (glioblastoma) being
most malignant [3]. Their diffuse infiltrative character
severely complicates glioma treatment. Whereas surgery
and radiotherapy mostly address the central part of the
tumor, cells that have migrated into the surrounding
brain tissue remain relatively unaffected and give rise to
recurrences. Although glioblastoma patient survival time
has slightly improved over the past decades, the prospect
with current treatment is only a median 15 months fol-
lowing diagnosis [4], urging for the development of
novel drug modalities to combat these tumors.
Diffuse gliomas can also be subdivided into several
classes based on molecular criteria. Lower grade (grade
II-III) gliomas and secondary grade IV glioblastomas
(arising from lower grade gliomas) display mutations in
isocitrate dehydrogenase genes (IDH1/2) in 80 % of the
cases [5]. Primary glioblastomas (originating de novo)
are wild type for IDH1 and IDH2 [6]. Presence of these
mutations is now often used as an independent predictor
of prolonged survival [7, 8]. Glioblastomas have been
further subdivided on the basis of transcriptional profiles
as cancers of the pro-neural, neural, mesenchymal and
classical subtype [9, 10]. Pro-neural and neural glioblast-
omas display IDH1/2 mutations, whereas classical and
mesenchymal gliomas often show loss of chromosome 10
(containing the tumor suppressor gene PTEN at 10q23),
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and/or amplification of chromosome 7 (containing the
proto-oncogene EGFR at 7p12) [3]. Constitutively active
mutant versions of receptor tyrosine kinases (RTKs), e.g.
EGFR (EGFRvIII), PDGFRA or MET (METΔ7–8 [11]),
are commonly encountered in primary glioblastomas [12].
As a result, in about 90 % of primary glioblastomas the
RTK/RAS/PI3K signaling pathway is affected by muta-
tions [10], underscoring deregulated phosphotyrosine-
based signaling as a major driver in glioma etiology.
Protein tyrosine phosphorylation is controlled via bal-
anced actions of protein tyrosine kinases and protein
tyrosine phosphatases (PTPs) [13]. Tumor cell biological
research has mostly focused on the druggable kinases,
and many tyrosine kinase genes are listed as proto-
oncogenes (e.g. EGFR, MET, ERBB2, and PDGFRA) [10].
Consequently, investigations on the counteracting, hence
potentially tumor suppressive, PTPs [13, 14] lag behind.
A well-known exception is PTEN [15, 16], the PTP fam-
ily member that is mutated or deleted in 41 % of primary
glioblastomas [10] and whose tumor suppressive action
is linked to its phospholipid phosphatase activity [17].
Although seemingly counter-intuitive, it has become
clear that some PTPs (e.g. SHP2, DUSP6 and PTPRZ1)
behave as oncogenes [18, 19]. Thus, the relevance of spe-
cific PTPs in certain cancer types is emerging [19, 20] but
PTPome studies in diffuse glioma specimens are lacking
so far.
We performed expression profiling of the PTP gene
family in diffuse glioma samples of different grades and
genetic backgrounds, and found that overall PTP expres-
sion levels decrease with increasing glioma grade and
appear independent of characteristic genetic aberrations.
Furthermore, for two of the PTPs whose expression
levels differed consistently and significantly between
lower grade (II-III) and high grade (IV, glioblastoma) gli-
omas and correlated with patient survival, we could
demonstrate tumor suppressive activity. These findings
highlight PTP impact on glioma tumorigenicity.
Materials and methods
Tumor samples and cell lines
Analyses of patient material were performed in accord-
ance with the guidelines of the local medical ethical
committee of the Radboud University Medical Center,
Nijmegen, The Netherlands. Patient glioma samples
(n = 83), comprising 19 grade II, 15 grade III and 49
grade IV tumors, were obtained from the archives of
the Radboud University Medical Center [see Additional
file 1]. Histologically normal brain control tissue (temporal
neocortex and white matter) was obtained from surgery
on epilepsy patients at the VU University Medical Center,
Amsterdam, The Netherlands.
HEK293FT cells were purchased from Invitrogen, LN-
229 glioblastoma cells were from the American Type
Culture Collection, and U-251 MG cells were kindly
provided by Joost Schalkwijk (Radboudumc). Derivation
and use of the xenograft-derived glioblastoma cell model
E98 has been described elsewhere [21]. U-251 MG,
LN-229, HEK293FT and E98 cells were cultured in
high glucose Dulbecco’s Modified Eagle Medium (Life
Technologies; cat.no.11960–044) supplemented with
10 % Fetal Bovine Serum (PAA laboratories; Cat.no.
A15–101), 4 mM glutamine and 1 mM pyruvate (Life
Technologies), at 37 °C in a humidified incubator under
7.5 % CO2. For some experiments 1 μM Gefitinib (Selleck
Chemicals), 4 mM 2-hydroxyglutarate (Sigma H8378), or
DMSO (solvent control) was added 48 h prior to isolation.
RNA isolation
Total RNA was isolated from frozen tumor material or
from cell lines. Ten 4 μm cryosections were homoge-
nized in 1.3 ml RNA-Bee (Tel-Test Inc., cs104B) through
mechanical dissociation. Next, 260 μl chloroform was
added and samples were vortexed and incubated on ice
for 15 min before being centrifuged at maximum speed
for 15 min at 4 °C. The top clear supernatant was trans-
ferred into a new tube and RNA was precipitated with 1
volume of isopropanol. The RNA pellet was dissolved in
400 μl NSE (50 mM NaAc, pH 5.2; 0.2 % SDS; 2 mM
EDTA in RNase-free water) and re-precipitated with
1 ml ethanol and collected by centrifugation (30 min at
4 °C, 14,000 g). The RNA pellet was briefly air-dried and
dissolved in 30 μl of RNase-free water. Concentrations
were determined on a NanoVue plus spectrophotometer
(GE Healthcare).
RT-reaction
Reverse transcriptase reactions were performed using
the iScripttm cDNA synthesis kit (Bio-Rad). RNA con-
centrations that were used ranged from 20 ng/μl to
2 μg/μl, and applied RNA and RT-mix volumes were ac-
cording to the manufacturers’ specifications. Synthesis of
cDNA was performed by incubating for 5 min at 25 °C,
followed by 30 min at 42 °C and 5 min at 85 °C. Result-
ing cDNA samples were diluted in distilled water (1:3 –
1:5) and stored at −80 °C until further use.
qRT-PCR
Validated qPCR primer sets for mRNA transcripts from
91 PTPs and housekeeping genes ACTB, CANX and
PSMB (described in [22]) were purchased from Qiagen
and SABiosciences. Transcript abundance was deter-
mined real-time in 10 μl reactions using SYBR GREEN
(Bio-Rad) and 3 μl of the diluted cDNA samples on a
CFX96™ system using the C1000™ Thermal Cycler (Bio-
Rad). PCR reactions were initialized at 95 °C for 15 min
and followed by 40 cycles of 15 s at 95 °C and 40 s at
60 °C. To monitor primer specificity, at the end of the
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last cycle a melting curve with increments of 0.5 °C was
recorded between 60 °C and 95 °C. PTP transcript
amounts were normalized to housekeeping gene expres-
sion levels (ΔCt). Normalization to any of three house-
keeping genes gave comparable results, and values
normalized towards ACTB are used here. The ΔCt values
are presented relative to the transcript levels in control
brain tissue, according to the ΔΔCt method of Livak and
Schmittgen [23]. The average expression level for a given
PTP was considered to be meaningfully different be-
tween tumor grades when p < 0.05 and │ΔΔCt│ > 1.5.
Tissue micro-array staining
Immunohistochemical stainings were performed on 4-μm
sections of tissue micro-arrays (TMAs) containing
formalin-fixed paraffin-embedded (FFPE) glioma (lower
grade, n = 16; high grade, n = 47). Slides were deparaffi-
nized and rehydrated according to standard methods.
Heat-induced epitope retrieval (HIER) was performed in
TRIS/EDTA buffer, pH 9 (Klinipath), for 10 min in a
microwave oven at 180 W. After cooling down, endogen-
ous peroxidase activity was blocked using 3 % H2O2 in
PBS for 10 min at room temperature. After washing
with PBS, primary antibodies against PTPRZ1 (BD
Transduction Laboratories; #610179), DUSP26 (Atlas
antibodies; HPA018221), MTMR4 (Pierce; #Pa5–13711),
or PTPRT (Ab frontier; #LFMA0345 clone T20–3C7)
were diluted in Normal Antibody Diluent (ImmunoLogic)
and incubated for 1 h at room temperature. Slides were
then washed with PBS and incubated with Poly-HRP-
GAM/R/R IgG (ImmunoLogic) as secondary antibody for
30 min at room temperature prior to detection with 3,3-
diaminobenzidine staining (Power-DAB, ImmunoLogic).
All sections were counter-stained with haematoxylin and
mounted in QuickD Mounting Medium (Klinipath).
Sections were scored by two observers (AB and KV),
after instructions and partly supervised by a neuro-
pathologist (PW), for intensity and percentage of cells
stained. Samples were binned into three classes: high
staining (high intensity staining, in the majority of
tumor cells), medium staining (lower intensity stain-
ing, in a considerable amount of tumor cells) and low
or no staining (low intensity or no staining, in a
minor part of the tumor cells). For DUSP26 we de-
fined a sample as low staining if there were positive
cells in the sample and as no staining if not a single
stained tumor cell was present.
Generation of cells with aberrant EGFR expression
Third generation lentiviral constructs that drive expres-
sion of wildtype (EGFR WT) or variant III (EGFRvIII)
epidermal growth factor receptor were generated as fol-
lows. A NotI linker (self-annealed 5′- CTA GTC CGG
GCG GCC GCC CGG A–3′) was ligated into the
cleaved XbaI site in PRK5-EGFR-WT (a mammalian
expression vector harboring wild-type human EGFR
cDNA, kindly provided by Reiner Lammers, Tübingen,
Germany). The resulting plasmid was digested using
NotI and HindIII and the EGFR WT-encoding fragment
was ligated into NotI/HindIII-digested pENTR/NotI-
XhoI [21]. EGFRvIII cDNA was obtained using primers
fw: 5′- GAT ATC ACC ATG CGA CCC TCC GGG–3′
and rev: 5′- CAG CGG CCG CTC ATG CTC CAA
TAA ATT CAC TG–3′ in a PCR reaction with an
EGFRvIII-positive glioblastoma cDNA pool as template.
The amplicon was digested with NotI and resulting
NotI/blunt-end EGFRvIII cDNA was ligated into HincII/
NotI-digested vector pENTR-1A (Invitrogen). Resulting
pENTR plasmids were subjected to an LR reaction
(Gateway® LR clonasetm II Enzyme mix; Invitrogen #
11791–020) with pLenti6.2/V5-DEST as destination vec-
tor, and pENTR/NotI-XhoI served to generate the empty
vector control.
Lentiviruses were generated in HEK293FT cells as de-
scribed earlier [21]. Small samples of virus-containing
medium were diluted 1:2 with methanol to monitor viral
titers by dot blot on nitrocellulose membranes (0.45 μM
Schleicher&Schuell #401196). After blocking for 30 min
with 3 % non-fat dry milk in TBST (10 mM Tris–HCl,
pH 8.0; 150 mM NaCl; 0.1 % Tween-20 (Sigma-Aldrich))
membranes were incubated with anti-VSV monoclonal
antibody P5D4 [24] in blocking buffer for 1 h. Mem-
branes were then washed three times for 10 min in
TBST and subsequently incubated with IRDye® 800CW-
conjugated goat-anti-mouse IgG (Li-COR Biosciences,
#926–32350) for 1 h at room temperature in the dark.
Blots were analyzed using the Odyssey imaging system
(LI-COR Biosciences).
U-251 MG glioblastoma cells were transduced with
lentiviral expression constructs for EGFR WT, EGFRvIII
or empty vector control, and cultured in blasticidin-
containing medium for 2 weeks. Resulting cell pools
were cultured for 48 h in presence or absence of
Gefitinib before being harvested for RNA and protein
isolation. RNA was used for qRT-PCR as described
above, to quantify transcript levels of three genes;
PTPRT, DUSP16 and PTPRG. Proteins from cell lysates
were size-separated on 8 % SDS-PAGE gels and immu-
noblotted as described previously [21] except that for
detection of phosphorylation-dependent epitopes 5 %
Bovine Serum Albumin in TBST was used as blocking
and incubation buffer. Primary antibodies were directed
against EGFR (rabbit 1:2000 SC03; #1005), pTyr (mouse
1:1000 pY20; sc508), and GAPDH (rabbit 1:5000; Cell
Signaling Technology #2118). Secondary antibodies were
IRDye-680- or −800-conjugated goat-anti-mouse and
goat-anti-rabbit antibodies. Detection was performed on
the Odyssey imaging system.
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Generation of glioblastoma cells with PTEN deletion
PTEN-deficient LN-229 cells were created using CRISPR/
Cas9 technology and a previously described PTEN target-
ing sequence [25] aimed at the start of the coding se-
quence in exon 1 of PTEN. Oligonucleotides that
contained the target sequence and overlapped with se-
quences in the receiving guide RNA expression plasmid
(PTEN-CRISPR-1-Fw: 5′- TTT CTT GGC TTT ATA
TAT CTT GTG GAA AGG ACG AAA CAC CGG ATC
GTT AGC AGA AAC AAA -3′; PTEN-CRISPR-1-Rev:
5′- GAC TAG CCT TAT TTT AAC TTG CTA TTT
CTA GCT CTA AAA CTT TGT TTC TGC TAA CGA
TCC -3′) were annealed and extended using Klenow
DNA Polymerase fragment. The PTEN CRISPR-1 hetero-
duplex was introduced into the AflII-linearized gRNA
cloning vector (a gift from George Church; Addgene plas-
mid # 41824 [26]) using Gibson assembly (New England
Biolabs) according to manufacturer’s instructions. PTEN
wildtype LN-229 glioma cells were transfected with a
1:1:0.1 mixture of the PTEN-targeting gRNA plasmid,
plasmid hCas (a gift from George Church; Addgene plas-
mid # 41815 [26]), and a GFP expression plasmid
(pLenti6/shSCR-GFP [21]), respectively, using jetPRIME
(Polyplus; Cat.no 114–07). Individual clones were derived
via limiting dilution and tested for successful CRISPR/
Cas9-mediated PTEN gene editing using a T7 endonucle-
ase I assay. Briefly, cells were lysed (100 mM Tris–HCl,
pH 7.5; 5 mM EDTA; 0.2 % SDS; 200 mM NaCl;
100 μg/mL Proteinase K) overnight at 50 °C. Subse-
quently, samples were cleared by centrifugation (5 min,
8,000 rpm) and DNA in the supernatant was precipitated
using an equal volume of isopropanol, washed once with
70 % ethanol, air-dried and finally dissolved in T10E0.1
(10 mM Tris–HCl, pH 8.0; 0.1 mM EDTA). Genomic
DNA was then used in a PCR reaction with Q5 polymer-
ase (NEB) containing Q5 GC enhancer according to man-
ufacturer’s instructions. Primers used were: PTEN-T7-fw:
5′-GGC TGG GAA CGC CGG AGA GT-3′ and PTEN-
T7-rev: 5′-CTA TCC TAC ATC ACC CCA TAG GG-3′.
Amplicons were purified using the NucleoSpin® Gel and
PCR Clean-up kit (Macherey-Nagel) and subjected to a
T7 endonuclease I digestion assay (NEB, M0302S) for
15 min according to manufacturer’s instructions. Clones
displaying edited PTEN alleles were further tested for
PTEN status through qRT-PCR and immunoblot analyses
as described above. Primary antibodies used were: rabbit
anti-PTEN (1:2,000, CST#9559), mouse anti-tubulin
monoclonal E7 (1:5,000; DSHB, University of Iowa), and
rabbit anti-pAKT-Ser473 (1:2,000; CST #4058).
PTPRT and DUSP26 expression constructs
PTPRT cDNA encompassing the full-length coding se-
quence was isolated from plasmid pGW-PTPRT (a kind
gift from Jae-Ran Lee, Daejeon, Korea) using BamHI and
NotI, and ligated into the corresponding sites in vector
pENTR/NotI-XhoI [21]. Similarly, plasmid pEF-HA-
DUSP26 (a kind gift from Rafael Pulido, Barakaldo,
Spain) was digested using EcoRI and XbaI and the
DUSP26 open reading frame was ligated into pENTR/
NotI-XhoI. An empty vector control (EV) was con-
structed as described above. An EGFP vector control
was generated by PCR (Fw: 5′- TAT AGG ATC CAT
GGT GAG CAA GGG CGA GG -3′; Rev: 5′- TAT ACT
CGA GTT ACT TGT ACA GCT CGT CC -3′) using
pEGFP as template, and the obtained amplicon was
digested with BamHI and XhoI and ligated into pENTR/
NotI-XhoI. All resulting plasmids were used in LR
Gateway® reactions (Invitrogen) using pLenti6/PGK-
DEST-TagRFP [21] as destination vector. Obtained
expression plasmids were used in HEK293FT cells to
produce lentiviruses, as described above. E98 human
glioblastoma cells [27] were lentivirally transduced twice,
and 3 days later further processed for glioma cell behav-
ior assays.
Proliferation and migration assays
E98 cells were grown on collagen I-coated (10 μg/cm2;
Invitrogen) coverslips to 60–80 % confluency over 48 h,
and incubated for 1 h with culture medium containing
10 μM EdU (5-ethynyl-2′-deoxyuridine). EdU incorpor-
ation was visualized using the click-iT® EdU Imaging kit
(Thermo Fisher Scientific, #C10086) via the manufac-
turers’ instruction. Coverslips were mounted on micro-
scope slides in DAPI-containing Mowiol (Sigma-Aldrich)
and images were collected on a Leica DMRA Fluorescence
microscope, equipped with a DFC340 FX CCD camera,
using 40x and 63x objectives. DAPI- and EdU-positive nu-
clei were counted automatically using FIJI software [28].
Migration of E98 cells was assessed in spheroid out-
growth assays as follows. E98 spheroids were generated
in hanging drops using methylcellulose (12 mg/mL;
Sigma, M6385) in DMEM supplemented with 10 % FCS
(2500 cells per spheroid). The next day, individual
spheroids were seeded in a 96-well imaging culture
dish (BD Falcon, #353219) on top of a confluent
mouse astrocyte layer in Matrigel-coated (30 μg/mL
PBS; BD Biosciences, #356237) culture wells. 24 h
later, cells were fixed and fluorescent (tagRFP) images
were collected. Average migration distance of cells
from spheroids (n > 37), calculated as change in radius
of the spheroid over 24 h, were analyzed semi-
automatically using FIJI software.
In silico analyses
REpository for Molecular BRAin Neoplasia DaTa
(REMBRANDT) was used to determine Kaplan-Meier
curves based on PTP transcript levels (as determined
via micro-array analyses) using the online Project
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Betastasis representation tool (http://betastasis.com/
glioma/rembrandt/). Threshold was set at median ex-
pression for the respective PTP transcript. RNA-seq
data from two different TCGA datasets (Brain Lower
Grade Glioma [29] and Glioblastoma Multiforme;
Provisional) were downloaded using cBioPortal (http://
www.cbioportal.org/index.do) [30, 31]. These represented
RNA-seq data of 166 IDH1 WT glioblastoma samples, 9
IDH1 mutant glioblastoma samples, 221 IDH1 mutant
lower grade glioma samples and 309 IDH1 WT lower
grade glioma samples.
Statistics
Statistical significance was tested using non-paired
two-tailed Student’s t-test or non-parametric Kruskal-
Wallis one-way analysis of variance with post-hoc
Dunn’s Multiple Comparison Test. Patient survival
data was automatically calculated by Project Betastasis
using a log-rank test. Heat map was generated in R
(version 3.0.1).
Results
Differential expression of PTP transcripts between lower
grade and high grade glioma samples
To investigate which members of the family of PTPs
play roles in the biology of gliomas of different grades,
we exploited a previously established and validated set of
qPCR primers for 91 human PTP transcripts [22] to
screen glioma specimens. Following cDNA synthesis and
qPCR, PTP transcript levels were determined relative to
those in control brain tissue. Strikingly, a pattern
emerged showing significantly lower overall PTP tran-
script levels in the glioblastoma samples as compared to
lower grade gliomas (Fig. 1a-b). In the first cohort of
samples, expression levels of 36 PTPs differed signifi-
cantly between lower grade (WHO grade II-III; n > 11)
and glioblastoma (WHO grade IV; n > 15) samples [see
Additional file 2]. To validate these findings, a second,
independent cohort was tested with these 36 primer sets
[see Additional file 3], resulting in the identification of
seven PTP genes (DUSP26, MTMR4, PTEN, PTPRM,
PTPRN2, PTPRT and PTPRZ1) that consistently and sig-
nificantly differed in expression between lower and high
grade gliomas (Fig. 1c).
To investigate whether differences in transcript levels
are reflected at the protein level, we performed immuno-
histochemical (IHC) staining on tissue micro-arrays con-
taining 47 glioblastoma, 16 lower grade glioma samples
and normal brain tissue. IHC could not be performed
for PTPRN2-encoded IA-2β protein due to lack of ap-
propriate antibodies. PTPRT protein levels were below
detection limits in both normal brain tissue and in gli-
oma tumor samples [see Additional file 4], in line with
the high qPCR Ct values obtained for this PTP. Reduced
PTEN and PTPRM protein levels in glioma specimens
have been well documented (e.g. [19, 32]). The other
PTPs were amenable for analysis by IHC. PTPRZ1
immunostainings revealed a clear membrane staining
that was higher in lower grade specimens than in high
grade counterparts (Fig. 2a), substantiating our RNA
data and earlier reports [19]. Immunodetection of
MTMR4 resulted in high signals in normal brain tis-
sue in structures resembling astrocytes (Fig. 2b). In
all samples (tumor and normal) also strong staining
of the neuropil could be observed, with some samples
additionally showing strong cytoplasmic staining in
tumor cells (Fig. 2biii). DUSP26 was detected in neu-
rons and neuropil of normal brain tissue but staining
was usually low or absent in tumor areas (Fig. 2c).
Low-level DUSP26 stainings were observed in 21 and
12 % of lower grade and glioblastoma samples, re-
spectively (Fig. 2d), in concordance with our qPCR
findings (Fig. 1c). Also MTMR4 expression levels
were higher in grade II-III gliomas than in glioblast-
oma samples (Fig. 2d), in line with our RNA expres-
sion data (Fig. 1c).
PTP expression patterns correlate with disease outcome
To corroborate our data, we performed in silico analysis
of RNA-seq data from two TCGA glioma datasets and
of micro-array data and survival probabilities as docu-
mented in the REMBRANDT brain tumor database. Out
of the seven PTPs, all but PTPRZ1 had significantly
lower expression levels in glioblastoma tumors as com-
pared to lower grade glioma samples (Fig. 3), in agree-
ment with our qPCR findings. Especially DUSP26 and
PTPRT show a very strong difference between grades.
PTPRZ1 is in fact overexpressed in both glioma sub-
groups as evident by the high RSEM RNA expression
values.
Using the Project Betastasis online representation tool,
we subdivided all available tumors represented in the
REMBRANDT dataset into low- and high-expressing
types on the basis of available RNA micro-array data for
our set of PTPs. Kaplan-Meier curves revealed a strong
and significant correlation between low DUSP26,
PTPRT, PTEN and PTPRM expression and disease pro-
gression (p < 0.001; Fig. 4a,f,c,d). MTMR4, PTPRN2 and
PTPRZ1 did not correlate with survival (Fig. 4b,e,g).
Also within the individual histological types (oligo-
dendroglioma (grade II-III), astrocytoma (grade II-III)
and glioblastoma (grade IV)) we observed expression-
dependent survival probabilities for DUSP26 and PTPRT
(data not shown). PTEN expression correlated with sur-
vival probability in glioblastoma and astrocytoma sam-
ples, while for PTPRM such an expression-dependent
effect only holds for glioblastoma specimens (data not
shown).
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Characteristic genetic aberrations in gliomas do not drive
PTP expression
Strikingly, for 80 out of the 91 PTP genes a pattern
emerged showing lower transcript levels in the glioblast-
oma samples as compared to lower grade gliomas
(Fig. 1a-b). This raises the question whether general PTP
profiles are influenced by characteristic genetic alter-
ations associated with lower grade glioma (frequently
IDH-mutant) or glioblastoma (e.g. EGFR amplification;
PTEN deletion) or rather reflect the tumor pathogenesis,
including cell of origin. To test this, U-251 MG glio-
blastoma cells were lentivirally transduced to over-
express EGFR or EGFRvIII. Phosphorylation of EGFR
and EGFRvIII was readily detected in the transduced
cells and was effectively blocked by treatment with the
EGFR inhibitor Gefitinib (Fig. 5a). The increased EGFR
signaling, however, did not influence expression levels
of three representative PTPs (DUSP16, PTPRG and
PTPRT; Fig. 5c) that displayed the grade-related ex-
pression pattern as observed for the majority of the
PTP cohort (Fig. 1a-b).
PTEN-inactivating deletions or mutations represent
another common aberration in primary glioblastoma
samples and could potentially explain the pattern ob-
served on the PTP transcripts. To genocopy PTEN
loss, the PTEN WT glioblastoma cell line LN-229 was
Fig. 1 Seven PTP genes display significantly different expression levels in lower grade gliomas and glioblastomas. a Heat map of qPCR-based PTP
expression levels – as determined in 19 WHO grade II, 15 WHO grade III and 49 WHO grade IV glioma samples – separated on malignancy grade
and normalized per PTP as Z-scores. PTPs are represented in reverse alphabetical order ranging from TNS3 at the top to ACP1 at the bottom. b
Overall PTP expression level difference between grade II, III or IV glioma samples and normal brain control tissue. The mean ΔΔCt value over the
91 PTP primer sets in the grade II, III or IV samples is plotted. Bars indicate SEM; black triangles in grade IV bar represent secondary glioblastoma
samples. Significance of mean expression differences between grades was calculated using Kruskal-Wallis one way analysis of variance with post-
hoc Dunn’s Multiple Comparison Test (n.s. indicates non significant; * p < 0.05; ***p < 0.001). c Graph showing differential expression between
lower grade (WHO grade II-III) and glioblastoma (WHO grade IV) glioma samples for seven PTPs on a 2log scale. PTP mRNA expression levels were
determined by qRT-PCR, normalized to β-actin transcript levels, and depicted relative to the levels in histologically normal brain tissue. Values
obtained in the first cohort of tumor samples are depicted [see Additional file 2]. Error bars indicate standard error of the mean (SEM). Asterisks
indicate significance levels (** p < 0.01; *** p < 0.001) as determined by the two-tailed Student’s t-test
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subjected to CRISPR/Cas9-mediated genome editing
and resulting clones were inspected for PTEN levels
and activity, respectively, as witnessed by PTEN and
phospho-AKT levels under low-serum conditions
(Fig. 5b). Although we successfully generated PTEN-
deficient LN-229 derivates and appropriate controls,
no significant changes in expression levels were ob-
served for the three representative reporter PTPs that
were tested (Fig. 5d).
We also monitored effects of the oncometabolite 2-
hydroxyglutarate (2-HG) that is produced in lower grade
gliomas and secondary glioblastomas as a result of the
characteristic IDH1R132H mutation and inhibits DNA
and histone demethylation. Tumor-relevant levels of 2-
HG were added for 48 h to U-251 MG (IDH1 wild type)
glioblastoma cells and potential changes in DUSP16,
PTPRG and PTPRT expression levels were monitored.
Addition of 2-HG significantly reduced the mRNA levels
for two out of the three PTPs measured (Fig. 5e). These
results are in line with epigenetic regulation of DUSP16
and PTPRG but do not explain the generally higher PTP
mRNA levels in IDH-mutant low-grade gliomas. RNA-
seq data from WT or IDH1 R132H-containing glioma
xenografts E434 and E478 [27, 33] also do not point to
an IDH-mutation associated difference in expression for
DUSP16, PTPRG and PTPRT (WPJL, unpublished data).
Collectively, these data make it rather unlikely that gen-
etic alterations characterizing lower grade glioma and
glioblastoma subgroups are major determinants of the
general PTP expression pattern observed (Fig. 1a,b).
Overexpression of DUSP26 or PTPRT in E98 glioblastoma
cells results in reduced tumorigenicity
DUSP26 and PTPRT are the most down-regulated PTPs
in gliomas with highest grade malignancy and both show
a pronounced correlation with survival probability
(Figs. 1, 3, 4). To test direct effects of expression on cell
behavior we overexpressed these PTPs in the E98 glio-
blastoma model [11, 21, 27, 34] and monitored effects
on cell growth and migration (Fig. 6). To facilitate
Fig. 2 Immunohistochemical analysis of PTPRZ1, MTMR4 and DUSP26 expression in normal brain and glioma tissue. Representative images of
formalin-fixed paraffin-embedded specimens stained with antisera against PTPRZ1 (a), MTMR4 (b) or DUSP26 (c). For PTPRZ1 and MTMR4 antisera,
immunostainings in (i) normal brain tissue, (ii) negative or low intensity tumor areas and (iii) high intensity tumor areas are provided. For anti-
DUSP26 a low staining example is shown in (iii). d Trichotome (PTPRZ1, MTMR4) and dichotome (DUSP26) analysis of PTP immunopositivity in
lower grade and high grade specimens. Percentages reflect the proportion of samples in the respective bin
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tracking of successfully transduced E98 cells, lentiviral
expression vectors were used that also carry a TagRFP
fluorescent reporter. DUSP26 and PTPRT protein ex-
pression of virus - producing HEK293FT was visualized
using immunoblotting [see Additional file 5]. Successful
overexpression of DUSP26 and PTPRT in E98 cells was
confirmed by qPCR (Fig. 6a,b) and E98 cell proliferation
capacity was investigated using EdU labeling of S-phase
cells. Increased DUSP26 or PTPRT levels led to reduced
EdU incorporation as compared to empty-vector con-
trols (Fig. 6c-d). This suppression of proliferation in the
E98 high grade glioma model following overexpression
of these two PTPs is in line with the observed positive
correlation with patient survival data.
To also monitor potential DUSP26 or PTPRT ef-
fects on glioblastoma cell migration, we turned to a
previously established spheroid outgrowth assay [4, 28].
Homogeneously-sized spheroids of lentivirally transduced
E98 cells, generated using the hanging-drop method, were
placed on a layer of mouse astrocytes and the migratory
performance of outgrowing fluorescent E98 cells was cal-
culated as the change in radius of the spheroid over 24 h.
Fig. 3 RNA-seq reveals PTP expression differences in lower grade glioma and glioblastoma. a-g Dot plots showing the mean estimated fraction
of transcripts per million as calculated in RSEM (RNA-Seq by Expectation-Maximization; horizontal black bars) and standard deviation for the
indicated PTP in lower grade glioma (WHO grades II-III; triangles) or glioblastoma (WHO grade IV; dots) tumor samples, as extracted from two
TCGA RNA-seq datasets. Asterisks indicate significance levels (***p < 0.001) as determined by the two-tailed Student’s t-test
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As compared to GFP-expressing control cells, the expres-
sion of either PTPRT or DUSP26 significantly reduced mi-
gration of E98 cells from the spheroid edge (Fig. 6e-f).
DUSP26 and PTPRT thus impinge on both growth and
motility of glioblastoma cells. Collectively, these data
underscore their involvement as tumor suppressors in gli-
oma, in line with the mRNA profiling data (Figs. 1, 3, 4).
Discussion
Diffuse gliomas are invariably fatal tumors, with most
glioblastoma patients surviving only up to 15 months
after diagnosis [3], stressing the need for more effective
treatment modalities. In this study we focused on the
protein tyrosine phosphatase gene family as alternative
entry points for treatment strategies. Seven out of
Fig. 4 Transcript levels of several PTPs correlate with patient survival probability. a-g Kaplan-Meier analysis of glioma patient survival data according to
low (red) and high (blue) PTP mRNA expression, obtained from microarray analyses on 524 glioma samples as present in the REMBRANDT repository.
Insets show histograms of PTP expression distribution with the vertical black line indicating the cutoff point (taken at the median expression level)
between low and high expressing samples. Asterisks indicate significance levels (***p < 0.001) calculated using the log-rank test in the Project Betastasis
online representation tool
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ninety-one investigated PTPs displayed significantly
different mRNA expression levels when comparing
lower and high grade gliomas. Furthermore, for four
out of these seven, expression levels correlated with
patient survival probability, underscoring their role in
tumor behavior. Importantly, overexpression of the
two PTPs that showed the largest expression differ-
ence in our qPCR and in silico analyses, DUSP26 and
PTPRT, resulted in reduced glioblastoma cell prolifer-
ation and migration, supportive of a tumor suppres-
sive role.
In general, PTP expression levels in lower grade gli-
omas resembled those in normal brain tissue whereas
levels in glioblastomas were generally lower. This overall
reduction in PTP expression with increasing grade may
relate to differences in the cell type of origin. Alterna-
tively, it may be imposed by characteristic genetic alter-
ations acquired during glioma development. We found
that experimental introduction of EGFR hyperactivity, or
of PTEN inactivation, in a glioblastoma cell line had no
effect on overall PTP expression patterns. Furthermore,
the transcriptional impact of 2-HG on PTP expression
in IDH1 wildtype glioblastoma cells was at best opposite
to the expected, and not able to tone down PTP mRNA
levels to those in lower grade gliomas or normal brain
tissue. These findings suggest that other differences in
tumor pathogenesis between lower and high grade tu-
mors are the major determinants for the PTP expression
pattern. The overall reduced PTP levels in glioblastomas
as compared to histologically normal brain and lower
grade tumor levels, points to PTP agonists as a potential
option for glioblastoma treatment.
In our screening rationale, stringent criteria led to a
selection of seven PTPs that differed significantly in their
expression between glioblastomas and lower grade gli-
omas. Our data revealing that PTEN expression was low
in high grade gliomas concords with literature data on
PTEN inactivation or absence in over one-third of high
grade gliomas, resulting in increased proliferation and
survival through activation of the PI3K/AKT pathway
[10, 35]. PTPRM has also been proposed as a glial tumor
suppressor (e.g. [19, 32]) and is consistently down-
regulated in high grade samples in our screen. Together
with its subfamily members PTPRU and PTPRK, they
are amongst the most frequently mutated PTPs in a
number of cancer types [16, 19, 20, 32, 36]. Some PTPs
that had previously been implicated in primary glioblast-
oma etiology [19] were not selected by our screen,
although some only just failed to reach our criteria (e.g.
PTPN11, encoding SHP2). This may reflect that such
Fig. 5 Characteristic mutations for lower/high grade gliomas exert no overt effect on PTP expression patterns. a Immunoblot of lysates from U-251
MG glioblastoma cells expressing wild-type EGFR, EGFRvIII or empty vector (EV) control. Cells were treated with the EGFR inhibitor Gefitinib (or DMSO
as solvent control) for 48 h before being lysed. Immunostaining (IB) was with antibodies against EGFR, phosphotyrosine (pY) or GAPDH (as loading
control). b Immunoblot analysis for PTEN and Ser473-phosphorylated AKT levels in parental and (PTEN-targeted) CRISPR/Cas9-treated LN-229 cells.
Lysates were prepared following 8 h of serum starvation (0.5 % FCS), and tubulin immunostaining served as loading control. c-e Analysis
of (ACTB-normalized) DUSP16, PTPRG and PTPRT transcript levels, as determined by qPCR, in cell models mimicking EGFR hyperactivity (c), PTEN defi-
ciency (d) or mutant IDH1-mediated 2-HG exposure (e). Bars indicate mean with SEM, asterisk represents significance level (* p < 0.05)
Bourgonje et al. Acta Neuropathologica Communications  (2016) 4:96 Page 10 of 14
PTPs could govern processes equally important to lower
grade and high grade tumors.
We found that PTPRZ1 expression is higher in lower
grade tumors than in high grade tumors, but in online
RNA-seq data the inverse was observed. This apparent
discrepancy may result from histopathological differ-
ences in the tumor collections. In the RNA-seq dataset,
a third of the lower grade samples represent astrocyto-
mas while in our sample cohort lower grade tumors
consisted mostly of oligodendroglial neoplasms with 1p/
19q co-deletion. PTPRZ1 is highly expressed in oligo-
dendrocyte precursor cells and is involved in normal
oligodendrocyte development [37, 38], thus providing ra-
tionale for the high PTPRZ1 expression in our sample
cohort. Irrespective, PTPRZ1 expression is consistently
up-regulated in all glioma specimens. We and others
have shown that the encoded transmembrane PTP acts
as an oncogene in gliomas [21, 39, 40] and, interestingly,
Fig. 6 DUSP26 and PTPRT suppress glioblastoma cell growth and motility. DUSP26 (a) and PTPRT (b) mRNA levels in lentivirally transduced E98
cells were determined by qRT-PCR. Expression, normalized to ACT-B, is given as fold change of that in GFP control cells. c Transduced E98 cells
were grown on coverslips for 48 h, pulse-labeled with EdU for 1 h, fixed, and EdU incorporation was visualized. Representative images of DAPI,
EdU and TagRFP positivity are depicted. d Percentage of EdU-positive nuclei among DAPI-stained cells was determined (n > 3). Error bars indicate
SD and asterisks reflect confidence levels (ANOVA; ** p < 0.01; *** p < 0.001). e Spheroids of transduced E98 cells on a confluent mouse astrocyte
layer were incubated for 24 h before being fixed. Representative images of TagRFP-expressing spheroids with outgrowing cells are shown for the
respective constructs. f The average radius increase (in pixels) due to migrating cells was calculated per spheroid from the data in (e), and plotted
as gray data points on top of the box plot for the mean with standard deviation. Asterisks indicate significance (*** p < 0.001; Kruskal-Wallis one
way analysis of variance p < 0.0001)
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two HLA-presented peptides derived from PTPRZ1’s
extracellular part are included in an experimental glioma
vaccine that is currently explored in phase II clinical
trials [41].
We additionally identified PTPRT, DUSP26, PTPRN2
and MTMR4 in our screen for glioma-relevant PTPs.
PTPRT belongs to the same cell adhesion molecule-like
PTP subfamily as PTPRM, PTPRU and PTPRK. Al-
though compelling evidence has put forward PTPRT as a
colon cancer susceptibility gene [20, 42–44], thus far no
reports have linked PTPRT to gliomas. PTPRT mRNA
levels are quite low in normal brain tissue and lower
grade gliomas but are still on average 40-fold higher
than those in high grade glioblastomas. In line with a
tumor suppressive role, we found that PTPRT overex-
pression significantly suppressed glioblastoma cell prolif-
eration and migration. The finding that the closely
related PTPRT and PTPRM show distinct expression
patterns in lower versus high grade gliomas (PTPRU just
failed to reach the criteria in the first cohort) and correl-
ate with patient survival, warrants further studies on
their role in glioma-associated signaling pathways.
DUSP26 represents a dual-specificity phosphatase, i.e.
it is able to dephosphorylate not only phosphotyrosines
but also phospho-serine and -threonine residues in sub-
strate proteins. In neuroblastoma cells DUSP26 dephos-
phorylates and inhibits the tumor suppressor p53 [45].
Furthermore, DUSP26 amplification has been found in
thyroid cancer, and DUSP26 knockdown impeded
growth of anaplastic thyroid cancer cells [46]. Collect-
ively, this indicates that DUSP26 acts as an oncogene,
and contrasts with our observation of low DUSP26
levels in glioblastomas in comparison with lower grade
glioma samples and normal brain tissue. Importantly, we
found that DUSP26 overexpression in E98 glioblastoma
cells resulted in decreased growth and motility. Other
investigators also reported on down-regulated DUSP26
levels in glioblastoma [47] and Tanuma and colleagues
additionally provided evidence that DUSP26 facilitates
catenin/cadherin delivery to cell-cell junction sites,
hence cell-cell adhesiveness [48]. It is becoming increas-
ingly clear that diffuse glioma cells form functional
networks via cell-cell contacts [49] and in such a context
DUSP26 protein may indeed have tumor suppressive
activity. Together with PTPRM and PTPRT, DUSP26
therefore holds promise for therapeutic intervention.
Intriguingly, PTPRN2 and MTMR4 both encode
PTPs that, like PTEN, have phosphoinositides as sub-
strates. PTPRN2 preferentially dephosphorylates phos-
phatidylinositol 4,5-bisphosphate (PI(4,5)P) [50] and
MTMR4 prefers phosphatidylinositol 3-phosphate (PI(3)P)
[51]. Whereas the tumor suppressive impact of PTEN’s
phospholipid phosphatase activity is beyond doubt [52],
only limited and contradicting data exist regarding
PTPRN2 involvement in cancer. The hypermethylation of
the PTPRN2 promoter region in glioblastomas and lung
adenocarcinomas [53, 54] suggests tumor suppressor
roles. In contrast, high PTPRN2 expression has been re-
ported to correlate with poor clinical outcomes in breast
cancer cases [55]. Furthermore, experimental down-
regulation of PTPRN2 in metastatic breast cancer cells
inhibited migratory potential and yielded smaller tumors
in vivo [56], rather pointing to oncogenic potential. The
tumor biological impact of PTPRN2 and MTMR4 may
thus be context-dependent, and how these PTPs feed into
glioma biology needs further investigation.
Conclusions
Taken together, our study – to our knowledge the
first comprehensive PTP mRNA profiling in diffuse
gliomas – highlights seven PTPs (DUSP26, MTMR4,
PTEN, PTPRM, PTPRN2, PTPRT and PTPRZ1) of
which expression decreases with increasing malignancy.
Largest expression differences between lower grade and
high grade diffuse gliomas were found for DUSP26 and
PTPRT. Their expression correlated with patient survival
probability, and overexpression inhibited glioblastoma cell
growth and motility. Together with PTPs that impinge
upon cellular contacts (DUSP26, PTPRZ1) and phospho-
lipid signaling (MTMR4, PTEN and PTPRN2) they pro-
vide novel cues to explore and design glioma treatment
options.
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